Prof William Abraham (Columbus, US) discusses GENETIC-AF - Phase ii trial of pharmacogenetic guided beta-blocker therapy with bucindolol vs. metoprolol for the prevention of atrial fibrillation/flutter in heart failure.
Filmed by Radcliffe Cardiology on site at HFA 2018 in Vienna, AT.